Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, discusses the potential of tailored treatment strategies and the importance of smoking cessation. It is important ...
Lupin is partnering with Mark Cuban Cost Plus Drug Company and the COPD Foundation, in an effort to bolster access to health care by expanding the availability of Tiotropium Bromide Inhalation Powder, ...
A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...
Please provide your email address to receive an email when new articles are posted on . Several clinicians expressed concern about inhaler costs for those with COPD in January. AstraZeneca, Boehringer ...
Please provide your email address to receive an email when new articles are posted on . Ensifentrine plus maintenance therapy yielded multiple benefits in patients with moderate to severe COPD. If ...
FLORENCE, Italy — Exacerbations remain one of the major unresolved challenges in the management of chronic obstructive pulmonary disease (COPD), despite the introduction of new therapies. However, ...
GREENWICH, Conn.--(BUSINESS WIRE)--An analysis from Cedar Gate Technologies (Cedar Gate) reveals that only 34.7% of commercially insured patients diagnosed with chronic obstructive pulmonary disease ...
Verona Pharma's stock soars into record territory after buyout deal with Merck Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant's portfolio of ...
Chronic obstructive pulmonary disease may be over-diagnosed among uninsured patients, unnecessarily increasing cost of care, according to a study to be presented at the 2013 American Thoracic Society ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback